Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Non-Current Deffered Revenue (2018)

Historic Non-Current Deffered Revenue for Northwest Biotherapeutics (NWBO) over the last 6 years, with Q4 2018 value amounting to $4.8 million.

  • Northwest Biotherapeutics' Non-Current Deffered Revenue changed N/A to $4.8 million in Q4 2018 from the same period last year, while for Dec 2018 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2018, which is N/A changed from last year.
  • Per Northwest Biotherapeutics' latest filing, its Non-Current Deffered Revenue stood at $4.8 million for Q4 2018.
  • In the past 5 years, Northwest Biotherapeutics' Non-Current Deffered Revenue ranged from a high of $4.8 million in Q4 2018 and a low of $4.8 million during Q4 2018